Table 3.

Overall survival statistics of patients in SEER–Medicare study of malignant mesothelioma diagnosed 2005–2009

Chemotherapy group	Surgery	Patients, n	Median survival, months (range)	Proportion surviving 1 year (95% CI)
All patients		1,625	8 (1–69)	0.31 (0.29–0.33)
	No	1,139	7 (1–69)	0.27 (0.24–0.3)
	Yes	486	10 (1–69)	0.41 (0.37–0.45)
No chemotherapy		898	4 (1–69)	0.17 (0.15–0.2)
	No	661	4 (1–69)	0.16 (0.14–0.19)
	Yes	237	5 (1–47)	0.2 (0.15–0.26)
Chemotherapy		727	12 (1–69)	0.48 (0.45–0.52)
	No	478	10 (1–68)	0.42 (0.37–0.46)
	Yes	249	14 (1–69)	0.61 (0.55–0.67)
One linea,b		473	9 (1–69)	0.35 (0.31–0.39)
	No	326	8 (1–68)	0.29 (0.24–0.34)
	Yes	147	12 (2–69)	0.48 (0.4–0.56)
Two linesa,c		172	15 (2–56)	0.64 (0.56–0.71)
	No	105	14 (2–55)	0.59 (0.49–0.68)
	Yes	67	16 (4–56)	0.72 (0.59–0.81)
One lineb,d		473	7 (1–68)	0.2 (0.15–0.26)
	No	326	6 (1–58)	0.2 (0.16–0.25)
	Yes	147	8 (1–68)	0.35 (0.27–0.43)
Two linesc,d		172	5 (1–33)	0.17 (0.12–0.23)
	No	105	5 (1–33)	0.17 (0.10–0.25)
	Yes	67	5 (1–25)	0.17 (0.09–0.27)

Notes:

^aSurvival months calculated from date of diagnosis for each patient;

^bexcluded 5 patients with surgery later than 9 months after diagnosis;

^cexcluded 1 patient with surgery later than 9 months after diagnosis;

^dsurvival months calculated from date of administration of chemotherapy agent (second line for two lines). This study used the linked SEER-Medicare database. The interpretation and reporting of these data are the sole responsibility of the authors. The authors acknowledge the efforts of the National Cancer Institute; the Office of Research, Development and Information, CMS; Information Management Services (IMS), Inc.; and the Surveillance, Epidemiology, and End Results (SEER) Program tumor registries in the creation of the SEER-Medicare database.²⁴

Abbreviations: SEER, Surveillance, Epidemiology, and End Results; CI, confidence interval.